Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06462700 · 1 trial · 1 indication
Hematologic response was considered to be "effective" when 2 or more of the following criteria were met: absolute neutrophil count greater than or equal to (\>=) 500 per microliters, platelet count \>=20,000 per microliters and reticulocyte count \>=60,000 per microliters was observed. In this outcome measure, number of participants with hematologic response classified as effective and not effective were reported. Improvement in counts that were dependent upon exogenously administered growth factors or transfusion, was not considered as fulfilling response criteria.
| Arm | Type | Description |
|---|---|---|
| PF-006462700 group | EXPERIMENTAL | All enrolled participants will be administrated PF-006462700. |
| Name | Type | Description |
|---|---|---|
| PF-06462700 | BIOLOGICAL | PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes. |
Inclusion Criteria: * Male or female participants between the ages of 2 years and more, inclusive, at Visit 1 (Screening). * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Have a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 1 | - | Anti-human thymocyte immunoglobulin, equine |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
PF-06462700 is an investigational monoclonal antibody being developed for the treatment of aplastic anemia, a condition where the bone marrow fails to produce enough blood cells. It is currently in Phase 3 clinical development, though the specific mechanism of action has not been disclosed.
PF-06462700 is being developed by Pfizer, Inc., a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 3 clinical development for aplastic anemia.
PF-06462700 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. A Phase 3 trial has been completed, but the drug remains under investigation for aplastic anemia.
PF-06462700 has one completed Phase 3 trial, identified as NCT04350606, which assessed its efficacy and safety in Japanese participants with aplastic anemia. The trial enrolled 3 participants and was not randomized or double-blinded.
No alternative names for PF-06462700 have been disclosed. It is identified solely by its investigational code, PF-06462700, and is being studied as a monoclonal antibody for aplastic anemia.